Skip to main content
Psychedex

3,4-CTMP

threo-3,4-dichloromethylphenidate

6Node page

what any key link opens

psx:substance/3-4-ctmp/value/contraindication/106a07e0-8288-49d1-8f12-36122c167695@1

valuereferenced by edges — no row of its own

derived from · upstream

feeds · downstream

none recorded

Closure of psx:substance/3-4-ctmp/value/contraindication/106a07e0-8288-49d1-8f12-36122c167695@1: 1 upstream, 0 downstream.

psx:substance/3-4-ctmp/value/contraindication/106a07e0-8288-49d1-8f12-36122c167695@1
└─ derived_from  proposal/contraindication/dc7f3268-47b2-4c03-b265-47c2464718c2  contraindication · other

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

138 with DOI

0 strong · 8 moderate · 5 weak

Compilations

22026-05-12T20:57:31.448Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

32last ruled 2026-06-04

0 awaiting a ruling

Issued documents

42026-10-19T20:29:31.236Z

notice · info card · emergency

Searches

202 with no results

queries and counts on the build

Claims checked

4112 supported

12 supported · 29 not

Correspondence

0received

consent field ships in Phase 4

Edges

160

derivations recorded for this entity

Complete over 13 sources, 2 compilations, and 32 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/3-4-ctmp/archive

2Build

one panel per compilation run

generation run 2026-05-11

12 min failedmodel not recordedplan not recordedrun/21f1c89b…

research

no artifact

draft

no artifact

audit

no artifact

verify

no artifact

simplify

no artifact

publish

no artifact

Selection

results seen0
selected by the model0
consumed as sources13

Verification

claims checked0
supported0
partially supported0
not supported0
inconclusive0
  • record
  • seen / partial
  • working

The model's own caveats

none raised on this run

Reproduce

inputs
13 source keys (listed under Sources)
plan
not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model
not recorded
streams
none — agent transcripts are persisted from 2026-09 onward

generation run 2026-05-12

61 min completedmodel pipeline-v5plan not recordedrun/4c3dc63a…

research

citationsRegistryrecordresearchOutputworking

draft

articleDraftworking

audit

articleAuditedworking

verify

verificationResultworking

simplify

articleSimplifiedworking

publish

runMetarecordrunSummaryrecord

Selection

results seen86
selected by the model23
consumed as sources13

Verification

claims checked41
supported12
partially supported0
not supported0
inconclusive29
  • record
  • seen / partial
  • working

The model's own caveats

  • sparse_evidence
  • structural_inference
  • sparse_evidence

Reproduce

inputs
13 source keys (listed under Sources)
plan
not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model
pipeline-v5
streams
none — agent transcripts are persisted from 2026-09 onward
20 searches — query, source, results, what was kept and why
20 searches for this run
#sourcequeryseenkeptrationale
1WebSearch3,4-CTMP legal status UK scheduling controlled substance 2015102Legal status data confirmed from official sources
2OpenAlex3,4-CTMP dichlorophenyl phenidate dopamine reuptake inhibitor11Relevant NPS review including phenidate class
3PubMed · absence3,4-CTMP dichlorophenyl methylphenidate analog pharmacology0——
4PubChem3,4-CTMP11Single unique match for 3,4-CTMP; all chemical identity data confirmed
5ACMD reportACMD methylphenidate NPS TCDO 20151—Could not extract text
6WebSearch3,4-CTMP dichlorophenyl methylphenidate pharmacology stimulant research chemical104Multiple background sources confirming key facts about 3,4-CTMP
7PubMedLuethi methylphenidate designer drugs dopamine transporter monoamine11Key in vitro pharmacology paper on phenidate NPS class including 3,4-CTMP
8PubMedDavidson Raby methylphenidate 3,4-CTMP ethylphenidate nucleus accumbens dopamine voltammetry11Only published in vitro study specific to 3,4-CTMP neurochemistry
9OpenAlexLuethi 2018 methylphenidate designer drugs DAT NET SERT 5-HT2B binding affinity in vitro21Mechanistic context for 3,4-CTMP DAT binding kinetics
10WebSearch3,4-CTMP Europe Sweden Austria Germany banned controlled substance101Comprehensive multi-jurisdiction legal status data
11PubMedUPLC-HRMS methylphenidate-derived new psychoactive substances metabolite identification in vitro in vivo11Only published metabolism study for 3,4-CTMP
12Erowid3,4-CTMP experience report dose onset duration11Primary user experience data supporting onset/duration characterization
13WebSearch3,4-CTMP binding affinity Ki IC50 DAT SERT NET transporter nanomolar101Key binding affinity values for pharmacology section
14Frontiers in Psychiatry (PMC)Davidson 2018 3,4-CTMP pharmacology in vitro11Primary pharmacology paper directly measuring 3,4-CTMP effects
15Erowid3,4-CTMP dose onset duration effects11Only detailed primary user experience data found; onset data contradicts DB seed value
16WebSearch3,4-CTMP legal status UK scheduling Class B 2017102Comprehensive legal status data across jurisdictions
17WebSearch3,4-CTMP stereochemistry diastereomer threo erythro enantiomer RR RS101Stereochemistry clarification for article
18MultipleCross-reference of DB seed data vs published/reported findings51Quality control cross-referencing for generation agent
19WebSearch3,4-CTMP pharmacokinetics metabolism half-life bioavailability CYP102Key pharmacokinetics finding - only published metabolism data for 3,4-CTMP
20ClinicalTrials.gov · absence3,4-CTMP dichlorophenyl methylphenidate0—Confirmed no clinical trials exist for this substance
41 claims by section — every cited sentence, checked against its source
comparative-pharmacology8 · 3 ok

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • The closest comparator is ethylphenidate, for which Maskell et al. (2016) documented 7 fatalities in the UK between February 2013 and January 2015, with blood concentrations of 0.026–2.18 mg/L; one death was attributed solely to ethylphenidate toxicity, four to mixed-drug toxicitysupported

    7 deaths with EPH in postmortem blood Feb 2013-Jan 2015. One sole EPH toxicity; 4 mixed drug toxicity; 2 hanging. Concentrations 0.026-2.18 mg/L in femoral blood. j.forsciint.2015.12.045

  • Davidson et al. (2018) directly compared 3,4-CTMP, ethylphenidate, and methylphenidate using fast cyclic voltammetry in adolescent male rat brain slices.supported

    3,4-CTMP (0.1 and 1 uM) increased evoked dopamine and noradrenaline efflux by ~6-fold and 2-fold, respectively, in rat brain slices. FCV used to measure DAT/NET effects. fpsyt.2018.00149

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • This is consistent with pharmacokinetic theories of abuse potential: compounds with slow onset of DAT occupancy produce less subjective "rush" and weaker conditioned reinforcement than rapid-onset inhibitors such as cocainesupported

    Slow-onset activity is important for limited abuse potential in stimulants. acsomega.3c02997

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

summary8 · 2 ok

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • The compound appeared on UK research chemical markets in 2013 and was subsequently scheduled in multiple jurisdictionssupported

    3,4-CTMP appeared on the UK drug market in 2013. fpsyt.2018.00149

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Despite its high potency, the slow oral onset (2–4 hours) tempers reinforcing effects relative to faster-acting DAT inhibitors.supported

    Slow-onset activity is important for limited abuse potential in stimulants. acsomega.3c02997

  • Claim in summary — inconclusiveinconclusiveworking →

pharmacology5 · 1 ok

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Manier et al. (2020) identified 7 phase I metabolites and no phase II metabolites using UHPLC-HRMS/MSsupported

    3,4-CTMP: 7 phase I metabolites, no phase II metabolites. Primarily hydrolyzed to carboxy metabolites. bkz052

receptor-pharmacology5 · 0 ok

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

safety5 · 0 ok

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

history3 · 2 ok

  • Claim in history — inconclusiveinconclusiveworking →

  • The research program was motivated by the cocaine antagonist hypothesis: a long-acting DAT inhibitor with slow onset might attenuate cocaine craving without producing the rapid reinforcing effects that sustain cocaine self-administrationsupported

    Slow-onset activity is important for limited abuse potential in stimulants. Related to methylphenidate SAR research. acsomega.3c02997

  • 3,4-CTMP appeared on the UK research chemical market in 2013, marketed as a "designer drug" in powder and pellet form via online vendorssupported

    3,4-CTMP appeared on the UK drug market in 2013. fpsyt.2018.00149

neuroscience3 · 2 ok

  • Davidson et al. (2018) demonstrated that 3,4-CTMP at 0.1–1 µM produces a ~6-fold increase in evoked dopamine efflux in rat nucleus accumbens slices — a magnitude exceeding that produced by 100-fold higher concentrations of the parent compoundsupported

    3,4-CTMP (0.1 and 1 uM) increased evoked dopamine and noradrenaline efflux by ~6-fold and 2-fold, respectively, in rat brain slices. fpsyt.2018.00149

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • DAT binding kinetics: Does 3,4-CTMP exhibit slow dissociation from DAT (low koff), and does this contribute to its prolonged duration independent of metabolic resistance? Niello et al. (2023) established that DAT binding persistence determines sustained psychostimulant effects, but this has not been directly measured for 3,4-CTMP.supported

    Drug-binding kinetics at DAT determine in vivo psychostimulant duration. Slow off-rate (koff) from DAT predicts more persistent in vivo effects vs cocaine and methylphenidate. pnas.2114204120

clinical-evidence2 · 0 ok

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

pharmacokinetic-detail2 · 2 ok

  • Manier et al. (2020) conducted the only published metabolism study of 3,4-CTMP, using UHPLC-HRMS/MS analysis of in vivo rat urine samples and in vitro incubations with pooled human liver S9 fraction.supported

    Metabolite identification of IPH, 4-FMPH and 3,4-CTMP using UHPLC-HRMS/MS. Rat urine + human S9 fraction. bkz052

  • Niello et al. (2023) demonstrated that persistent binding at the dopamine transporter — rather than plasma half-life alone — determines sustained psychostimulant effectssupported

    Drug-binding kinetics at DAT determine in vivo psychostimulant duration. Slow off-rate (koff) from DAT predicts more persistent in vivo effects vs cocaine and methylphenidate. pnas.2114204120

3Sources

13 consumed · sorted by year · feeds = sections resting on it

Sources
yearsourcetierstatusfeeds
20243,4-Dichloromethylphenidate - PubChem Compound CID 44296390National Center for Biotechnology Information (NCBI)url:208968189852396cmoderateconsumedcited only
2023Chiral Resolution of the Enantiomers of the Slow-Onset Dopamine Reuptake Inhibitor CTDP-32476 and Their ActivitiesFroimowitz M, Taboada R, Poulos ZJ, Rainone DJ, Imler GH, Gardner EL, Kelley CJ · ACS Omegadoi:10.1021/acsomega.3c02997moderateconsumed4 sections
2023Persistent binding at dopamine transporters determines sustained psychostimulant effectsNiello M, Sideromenos S, Gradisch R, O'Shea R, et al. · Proceedings of the National Academy of Sciencesdoi:10.1073/pnas.2114204120moderateconsumed2 sections
2022Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017–2020: A ReviewMohr ALA, Logan BK, Fogarty MF, Krotulski AJ, Papsun DM, et al. · Journal of Analytical Toxicologydoi:10.1093/jat/bkac023moderateconsumed2 sections
2020Use of UPLC-HRMS/MS for In Vitro and In Vivo Metabolite Identification of Three Methylphenidate-derived New Psychoactive SubstancesManier SK, Niedermeier S, Schäper J, Meyer MR · Journal of Analytical Toxicologydoi:10.1093/jat/bkz052moderateconsumed2 sections
2018In Vitro Neurochemical Assessment of Methylphenidate and Its "Legal High" Analogs 3,4-CTMP and Ethylphenidate in Rat Nucleus Accumbens and Bed Nucleus of the Stria TerminalisDavidson C, Raby CAR, Barrese V, Ramsey J · Frontiers in Psychiatrydoi:10.3389/fpsyt.2018.00149moderateconsumed5 sections
2018Pharmacological profile of methylphenidate-based designer drugsLuethi D, Kaeser PJ, Brandt SD, Krähenbuhl S, Hoener MC, Liechti ME · Neuropharmacologydoi:10.1016/j.neuropharm.2017.08.020moderateconsumed5 sections
2017UK Misuse of Drugs Act 1971 (Amendment) Order 2017 - Class B scheduling of methylphenidate NPSUK Home Officeurl:fad571eb1571108dweakconsumedcited only
2016Seven fatalities associated with ethylphenidate.Maskell PD, Smith PR, Cole R, Hikin L, Morley SR · Forensic Science Internationaldoi:10.1016/j.forsciint.2015.12.045weakconsumed1 section
2015UK Temporary Class Drug Order: Methylphenidate-based NPS (ACMD Report, April 2015)Advisory Council on the Misuse of Drugs (ACMD)url:ec0798ba86d0bb86weakconsumedcited only
2015UNODC Early Warning Advisory: UK temporarily bans five methylphenidate-related NPS (April 2015)UNODCurl:cd066895e93f8534weakconsumedcited only
20143,4-Dichloromethylphenidate Experience Report: 'Second Time Around'Anonymous (Erowid user)url:99e99262fcb39db7weakconsumedcited only
1996Synthesis and Pharmacology of Potential Cocaine Antagonists. 2. Structure-Activity Relationship Studies of Aromatic Ring-Substituted Methylphenidate AnalogsDeutsch H, Shi Q, Gruszecka-Kowalik E, Schweri M · Journal of Medicinal Chemistrydoi:10.1021/jm950697cmoderateconsumed6 sections
—Searched ClinicalTrials.gov for "3,4-CTMP dichlorophenyl methylphenidate" — no resultsabsenceno results—
—Searched PubMed for "3,4-CTMP dichlorophenyl methylphenidate analog pharmacology" — no resultsabsenceno results—

4Docket

one filing per activity — decisions, correspondence, reports

  1. 0012026-05-12revisionRevision 1

    Initial LLM generation (v5 pipeline, wiki, prose phase)

    psx:substance/3-4-ctmp/version/1
  2. 0022026-06-04proposal30 value proposals approved together

    one review action inferred from a shared reviewer and instant — the graph records one activity per proposal

    30 items in this filing

    • contraindication · other
    • contraindication · neurological
    • contraindication · cardiovascular
    • contraindication · psychiatric
    • contraindication · psychiatric
    • contraindication · hepatic
    • contraindication · other
    • contraindication · pregnancy_breastfeeding
    • dose_tier · threshold
    • dose_tier · light
    • dose_tier · common
    • dose_tier · strong
    • dose_tier · heavy
    • timeline · oral · onset
    • timeline · oral · come_up
    • timeline · oral · peak
    • timeline · oral · resolution
    • timeline · oral · afterglow
    • toxicity
    • dependence · full
    • withdrawal
    • tolerance
    • dosage · oral
    • duration · oral · onset
    • duration · oral · come_up
    • duration · oral · peak
    • duration · oral · offset
    • duration · oral · total
    • duration · oral · aftereffects
    psx:substance/3-4-ctmp/proposal/contraindication/3ba0edf6-c1ea-4437-a5c8-5687f1a646ed
  3. 0032026-06-04publicationPublication — backfill
    psx:substance/3-4-ctmp/pub/7ba3fee3-8094-488a-9682-877fe74508f8

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
documentcontent hashissuedfrom versionsuperseded
info_card356907db9c3aafc83bba839a…2026-10-19 20:29Revision 1current
emergency58d3299a8754d788e3d74c0e…2026-09-04 04:27Revision 1current
info_cardf3510a9b76148185a09fbe8e…2026-09-04 04:27Revision 1superseded2026-10-19
notice73cf22db1358416d526aa30d…2026-09-04 04:27Revision 1current